UT Tyler Awarded $211,000 NIH Grant to Help Improve Pulmonary Medications
July 12, 2023
UT Tyler Awarded $211,000 NIH Grant to Help Improve Pulmonary Medications
Office of Marketing and Communications
Follow @UTTyler TweetJuly 12, 2023
Media Contact: Hannah Buchanan
Editor/Writer–Strategic Communications & Media Relations
Marketing and Communications
The University of Texas at Tyler
903.539.7196 (cell)
The University of Texas at Tyler was awarded $211,000 by the National Institutes of Health to help improve blood-clotting medications for treatments in lung disorders and diseases.
The project is designed to identify dosing of fibrinolytic, or clot-busting, agents that can be safely and effectively administered to the compartment surrounding the lung to dissolve clots large enough to impair lung function. Dr. Steven Idell, UT Tyler professor of medicine and senior vice president for research, serves as principal investigator for the one-year NIH project.
This research could positively impact those with chest trauma with bleeding and retained clot formation and other forms of bleeding, including post-surgical bleeding, or coagulation disorders, such as those associated with cancer, that may cause a hemothorax – when blood collects in the space between the lung and chest wall, or pleural cavity, according to Idell.
“The results will inform dosing in anticipation of clinical trial testing that is currently scheduled to begin early in 2024 and sponsored by the clinical stage start-up company called Lung Therapeutics, Inc.,” said Idell, a UT Tyler Health Science Center pulmonary physician and researcher who has collaborated with NIH for more than 35 years.
The grant, sponsored by funding from NIH’s National Heart, Lung and Blood Institute, is part of the new CATALYZE funding mechanism to support translational science by funding projects that can soon enter clinical trial testing.
Idell is internationally known for his research in the causes and treatment of pulmonary fibrosis, or lung scarring. Other co-investigators who are involved in lung/respiratory research are Dr. Ali Azghani, UT Tyler professor of biology; Dr. Andrey Komissarov, UT Tyler professor of cellular and molecular biology; and Dr. Galina Florova, UT Tyler associate professor of cellular and molecular biology.
Azghani, who joined the UT Tyler faculty in 1998, studies lung function and bacteria that causes lung disease. Komissarov joined the UT Tyler Health Science Center in 2007 and examines fibrinolytic agents and their usage in pleural injury. Florova joined the UT Tyler Health Science Center in 2009 and investigates these same forms of therapeutics.
The National Institutes of Health, a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives. For more information, visit nih.gov/.
With a mission to improve educational and health care outcomes for East Texas and beyond, UT Tyler offers more than 90 undergraduate and graduate programs to nearly 10,000 students. Through its alignment with UT Tyler Health Science Center and UT Health East Texas, UT Tyler has unified these entities to serve Texas with quality education, cutting-edge research and excellent patient care. Classified by Carnegie as a doctoral research institution and by U.S. News & World Report as a national university, UT Tyler has campuses in Tyler, Longview, Palestine and Houston.